The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...